Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Pricing and Reimbursement in Oncology - Introduction | 8 | 1 |
| Pricing and Reimbursement in Oncology - Overview | 9 | 7 |
| Development of Oncology Drugs | 12 | 1 |
| Market Access and the Role of Health Economics in Cancer Drugs | 13 | 1 |
| Regulation of Cancer Drugs in Europe | 13 | 1 |
| Hospital Budgets and Patient Access to Drugs | 13 | 1 |
| Payers Managing Influx of New Therapies through Innovative Strategies | 14 | 1 |
| Risk Sharing Agreements in the US Vis- -vis Europe | 15 | 1 |
| Difference in Reimbursement for Oncology Drugs between the US and Europe | 15 | 1 |
| Rationalizing Costs in the US | 15 | 1 |
| Pricing and Reimbursement in Oncology - The US | 16 | 11 |
| Introduction | 16 | 1 |
| Regulatory Bodies | 17 | 1 |
| Trends | 18 | 1 |
| Oncology Practice and Expenditure in the US | 18 | 1 |
| Expenditure on Cancer Care Until 2020 - Costs May Increase by 27% from 2010 | 18 | 6 |
| Reimbursement of Prescription Drugs - Oncology Falls under Tier Four | 24 | 1 |
| Strategies to Control Healthcare Spending | 24 | 1 |
| Oral Targeted Chemotherapeutics are the Next Paradigm in Cancer Care | 25 | 1 |
| Reimbursement Issues in Oral Chemotherapeutics | 25 | 1 |
| Oral Chemotherapy Parity Act | 26 | 1 |
| Pricing and Reimbursement in Oncology - Top Five Countries of Europe | 27 | 28 |
| Italy | 27 | 1 |
| Introduction | 27 | 1 |
| Regulatory Bodies | 28 | 1 |
| Trends | 29 | 1 |
| Faster Implementation of AIFA-approved Innovative Drugs in Regional Formularies Likely to Benefit Expensive Oncology Therapeutics | 29 | 1 |
| New List of Innovative Drugs that Regions are Obligated to Reimburse Does Not Include Oncology Therapeutics | 30 | 1 |
| Conditional Reimbursement for Expensive Oncology Drugs in Italy Since 2006 | 30 | 1 |
| New Reimbursement Decisions for Innovative Novel Cancer Drugs Unlikely to Improve Italy s Picture | 31 | 1 |
| Spain | 31 | 1 |
| Introduction | 31 | 1 |
| Regulatory Bodies | 31 | 1 |
| Trends | 32 | 1 |
| Royal Decree Law to Further Bring Down Public Pharmaceutical Expenditure | 33 | 1 |
| Regional Health Authority Initiatives to Curb Pharmaceutical Expenditure by Limiting Oncology Drug Supply | 33 | 1 |
| Rebates Imposed on Patented and Orphan Medicines | 34 | 1 |
| Germany | 34 | 1 |
| Introduction | 34 | 1 |
| Regulatory Bodies | 35 | 2 |
| Trends | 37 | 1 |
| Pay-For-Performance; a Restricted Reimbursement Strategy in Oncology and an Emerging Trend | 37 | 1 |
| Cost-Containing Measures According to the AMNOG - For Patented Drugs | 37 | 1 |
| Impact of Pricing Reform - Pharmaceutical Manufacturers will no Longer be Able to Fix Prices | 38 | 1 |
| Expansion of the Reference-Pricing System | 38 | 1 |
| A Rebate of 16% on Non-Reference Drug Sales - Further Cost Containment | 38 | 1 |
| Rebate Contracts between Health Insurance Funds and Manufacturers of Generics | 38 | 1 |
| France | 39 | 1 |
| Introduction | 39 | 2 |
| Regulatory Bodies | 41 | 2 |
| Trends | 43 | 1 |
| Healthcare Budget Cut to Impact Pharmaceuticals Growth in 2012 | 43 | 1 |
| Pharmaceutical Price Cuts Including Parallel Import Drugs | 43 | 1 |
| CEPS Adjustments to Drug Pricing Methods | 44 | 1 |
| Generics Substitution Missed Targets in 2010 | 44 | 1 |
| CEPS Imposes Reference Prices for Branded Antihypertensive from 2011 | 44 | 1 |
| Reimbursement Restrictions for Drugs with Limited Clinical Merit Rating | 45 | 1 |
| Exclusion of Benign Hypertension from Reimbursement | 45 | 1 |
| Reimbursement Cuts for Drugs with Moderate Clinical Benefit and Medical Devices | 46 | 1 |
| Swift End to Reimbursement of Drugs that Offer Minimal Clinical Benefit | 46 | 1 |
| The UK | 47 | 1 |
| Introduction | 47 | 1 |
| Regulatory Bodies | 48 | 2 |
| Trends | 50 | 1 |
| Cancer Drugs Fund in the UK, Until the Set Up of Value Based Pricing in 2014 | 50 | 1 |
| Multi-pronged Benefits of the Cancer Fund | 51 | 1 |
| Market Entry Restrictions for Cancer Drugs in the UK Lead the Way for Risk-Sharing Schemes | 51 | 1 |
| Present PPRS Introduced in 2009 - Key Points | 52 | 1 |
| Value-Based Pricing in the Future | 53 | 2 |
| Pricing and Reimbursement in Oncology - Japan | 55 | 5 |
| Introduction | 55 | 2 |
| Regulatory Bodies | 57 | 1 |
| Trends | 58 | 1 |
| Fee Changes for the Elderly in Japan Suffering from Cancer | 58 | 1 |
| Off-label Uses of Drugs Agreed to be Given Conditional Reimbursement | 58 | 1 |
| Changes to Japan s Pricing System for Market Leading Drugs | 58 | 1 |
| New Medicines Included in NHI List Including Eisai s Breast Cancer Drug Halaven | 58 | 2 |
| Pricing and Reimbursement in Oncology - Appendix | 60 | 6 |
| Market Definitions | 60 | 1 |
| Abbreviations | 60 | 3 |
| Sources | 63 | 1 |
| Research Methodology | 64 | 1 |
| Introduction | 64 | 1 |
| Regulatory Bodies | 64 | 1 |
| Key Trends | 64 | 1 |
| Contact Us | 65 | 1 |
| Disclaimer | 65 | 1 |
